<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898442</url>
  </required_header>
  <id_info>
    <org_study_id>TicagSTEMI</org_study_id>
    <nct_id>NCT01898442</nct_id>
  </id_info>
  <brief_title>High Ticagrelor Loading Dose in STEMI</brief_title>
  <official_title>Pharmacodynamic Profiles of Ticagrelor in Patients With ST Elevation Myocardial Infarction: A Randomized Comparison of Different Loading Dosage Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ticagrelor is a reversible direct acting P2Y12 antagonist, which has shown to be superior to
      clopidogrel, in adjunct to aspirin, in preventing recurrent ischemic events. Ticagrelor is
      considered a first line therapy to be administered as soon as possible in ACS patients.
      However, the pharmacodynamic effects of ticagrelor at the recommended 180mg loading dose are
      delayed in patients with STEMI undergoing primary PCI. The use of higher loading dose
      regimens of ticagrelor has therefore been advocated. The proposed investigation will have a
      prospective, randomized, parallel design in which STEMI patients undergoing primary PCI will
      be randomized to receive three different loading dose of ticagrelor (180 mg, 270 mg and 360
      mg). Pharmacodynamic testing will be performed at several time points to test our study
      hypothesis that a higher loading dose regiment will achieve more promptly enhanced platelet
      inhibitory effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dual antiplatelet therapy consisting of aspirin and a P2Y12 receptor antagonist is the
      cornerstone of treatment for prevention of thrombotic events in patients with acute coronary
      syndromes (ACS). Ticagrelor is a reversible direct acting P2Y12 antagonist, which has shown
      to be superior to clopidogrel, in adjunct to aspirin, in preventing recurrent ischemic
      events, including cardiovascular mortality. Ticagrelor was recently approved for clinical use
      in ACS patients, at a dose of 180 mg loading dose and 90 mg twice/day maintenance dose.
      Ticagrelor is considered a first line therapy to be administered as soon as possible in ACS
      patients, including those presenting with ST-elevation myocardial infarction (STEMI)
      undergoing primary percutaneous coronary intervention (PCI). However, there are discordant
      data on the onset of its antiplatelet effects in this particular setting. In particular, the
      pharmacodynamic effects of ticagrelor at the recommended 180mg loading dose are delayed in
      patients with STEMI undergoing primary PCI. The use of higher loading dose regimens of
      ticagrelor has therefore been advocated. However, if the administration of a higher
      ticagrelor loading dose may overcome this limitation is still unknown and represents the aim
      of our study. The proposed investigation will have a prospective, randomized, parallel design
      in which STEMI patients undergoing primary PCI will be randomized to receive three different
      loading dose of ticagrelor (180 mg, 270 mg and 360 mg). Pharmacodynamic testing will be
      performed at several time points to test our study hypothesis that a higher loading dose
      regiment will achieve more promptly enhanced platelet inhibitory effects. This study will
      provide insights on the pharmacodynamic effects of higher ticagrelor loading doses and will
      help clinicians choose the most appropriate treatment to avoid complications related to
      inadequate platelet inhibition in the early phase of patients with STEMI undergoing primary
      PCI.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Reactivity by VerifyNow P2Y12</measure>
    <time_frame>1 hour</time_frame>
    <description>The primary end-point of the study was the comparison of the P2Y12 reaction units (PRU) determined by VerifyNow P2Y12 at 1 hour after administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity by VerifyNow P2Y12 at Other Time Points</measure>
    <time_frame>30 min and 2, 4, 8, 24 hours</time_frame>
    <description>Secondary outcomes included the comparison of the P2Y12 reaction units (PRU) determined by VerifyNow P2Y12 at 30 min and 2, 4, 8, 24 hours after ticagrelor loading dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity by Vasodilator-stimulated Phosphoprotein (VASP) at All Time Points</measure>
    <time_frame>30 min and 1, 2, 4, 8, 24 hours</time_frame>
    <description>Secondary outcomes included the comparison of the platelet reactivity index (PRI) determined by vasodilator-stimulated phosphoprotein (VASP) at 30 min and 1, 2, 4, 8, 24 hours after ticagrelor loading dose administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profiles of Ticagrelor (Tmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic assessments included determination of plasma concentration of ticagrelor. Time for the maximum plasma concentration (Tmax), maximum observed plasma concentration (Cmax) and the area under the plasma concentration vs. time curve from time 0 to the last measurable concentration (AUC0-t) were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profiles of Ticagrelor (Cmax)</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic assessments included determination of plasma concentration of ticagrelor. Time for the maximum plasma concentration (Tmax), maximum observed plasma concentration (Cmax) and the area under the plasma concentration vs. time curve from time 0 to the last measurable concentration (AUC0-t) were calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profiles of Ticagrelor (AUC0-t)</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic assessments included determination of plasma concentration of ticagrelor. Time for the maximum plasma concentration (Tmax), maximum observed plasma concentration (Cmax) and the area under the plasma concentration vs. time curve from time 0 to the last measurable concentration (AUC0-t) were calculated.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Ticagrelor 180</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard ticagrelor 180mg loading dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor 270mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High ticagrelor 270mg loading dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor 360mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High ticagrelor 360mg loading dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 180mg</intervention_name>
    <description>Rndomization to standard or high ticagrelor loading dose regimens</description>
    <arm_group_label>Ticagrelor 180</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 270mg</intervention_name>
    <description>Randomization to standard or high loading dose regimen</description>
    <arm_group_label>Ticagrelor 270mg</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 360mg</intervention_name>
    <description>Randomization to standrad or high loading dose regimen</description>
    <arm_group_label>Ticagrelor 360mg</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ST-elevation myocardial infarction undergoing primary PCI.

          -  Age between 18 and 80 years old.

        Exclusion Criteria:

          -  History of prior intracranial bleeding.

          -  On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel,
             ticagrelor) in past 30 days.

          -  Known allergies to aspirin or ticagrelor.

          -  On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban).

          -  Treatment with IIb/IIIa glycoprotein inhibitors.

          -  Fibrinolytics within 24 hours

          -  Known blood dyscrasia or bleeding diathesis.

          -  Known platelet count &lt;80x106/mL.

          -  Known hemoglobin &lt;10 g/dL.

          -  Active bleeding.

          -  Hemodynamic instability.

          -  Known creatinine clearance &lt;30 mL/minute.

          -  Known severe hepatic dysfunction.

          -  Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker
             protection.

          -  Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction
             with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin,
             nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and
             telithromizycin.

          -  Pregnant females*.

               -  Women of childbearing age must use reliable birth control (i.e. oral
                  contraceptives) while participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominick Angiolillo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2013</study_first_submitted>
  <study_first_submitted_qc>July 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <results_first_submitted>May 26, 2015</results_first_submitted>
  <results_first_submitted_qc>May 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 8, 2015</results_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>platelet function</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>STEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between September 2013 and June 2014.</recruitment_details>
      <pre_assignment_details>There were a total of 129 STEMI activations; of these, 52 patients provided their written informed consent to participate in the study and were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ticagrelor 180mg</title>
          <description>Standard ticagrelor 180mg loading dose
Ticagrelor 180mg: Randomization to standard ticagrelor loading dose</description>
        </group>
        <group group_id="P2">
          <title>Ticagrelor 270mg</title>
          <description>High ticagrelor 270mg loading dose
Ticagrelor 270mg: Randomization to a high ticagrelor loading dose regimen</description>
        </group>
        <group group_id="P3">
          <title>Ticagrelor 360mg</title>
          <description>High ticagrelor 360mg loading dose
Ticagrelor 360mg: Randomization to a high ticagrelor loading dose regimen</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Hemolysis/technical problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient vomited pills</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The primary population was used for analysis of baseline characteristics and primary and secondary endpoints. The primary population was defined as patients who received the randomized loading dose of study medication and had at least 75% of valid data, which needed to include the primary endpoint time point.</population>
      <group_list>
        <group group_id="B1">
          <title>Ticagrelor 180mg</title>
          <description>Standard ticagrelor 180mg loading dose
Ticagrelor 180mg: Randomization to standard ticagrelor loading dose</description>
        </group>
        <group group_id="B2">
          <title>Ticagrelor 270mg</title>
          <description>High ticagrelor 270mg loading dose
Ticagrelor 270mg: Randomization to a high ticagrelor loading dose regimen</description>
        </group>
        <group group_id="B3">
          <title>Ticagrelor 360mg</title>
          <description>High ticagrelor 360mg loading dose
Ticagrelor 360mg: Randomization to a high ticagrelor loading dose regimen</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="8.6"/>
                    <measurement group_id="B2" value="58" spread="8.5"/>
                    <measurement group_id="B3" value="57" spread="12.1"/>
                    <measurement group_id="B4" value="58" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Platelet Reactivity by VerifyNow P2Y12</title>
        <description>The primary end-point of the study was the comparison of the P2Y12 reaction units (PRU) determined by VerifyNow P2Y12 at 1 hour after administration</description>
        <time_frame>1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 180mg</title>
            <description>Standard ticagrelor 180mg loading dose
Ticagrelor 180mg: Randomization to standard ticagrelor loading dose</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 270mg</title>
            <description>High ticagrelor 270mg loading dose
Ticagrelor 270mg: Randomization to a high ticagrelor loading dose regimen</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 360mg</title>
            <description>High ticagrelor 360mg loading dose
Ticagrelor 360mg: Randomization to a high ticagrelor loading dose regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity by VerifyNow P2Y12</title>
          <description>The primary end-point of the study was the comparison of the P2Y12 reaction units (PRU) determined by VerifyNow P2Y12 at 1 hour after administration</description>
          <units>PRU</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188" spread="20"/>
                    <measurement group_id="O2" value="125" spread="23"/>
                    <measurement group_id="O3" value="228" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.017</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity by VerifyNow P2Y12 at Other Time Points</title>
        <description>Secondary outcomes included the comparison of the P2Y12 reaction units (PRU) determined by VerifyNow P2Y12 at 30 min and 2, 4, 8, 24 hours after ticagrelor loading dose administration</description>
        <time_frame>30 min and 2, 4, 8, 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 180mg</title>
            <description>Standard ticagrelor 180mg loading dose
Ticagrelor 180mg: Randomization to standard ticagrelor loading dose</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 270mg</title>
            <description>High ticagrelor 270mg loading dose
Ticagrelor 270mg: Randomization to a high ticagrelor loading dose regimen</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 360mg</title>
            <description>High ticagrelor 360mg loading dose
Ticagrelor 360mg: Randomization to a high ticagrelor loading dose regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity by VerifyNow P2Y12 at Other Time Points</title>
          <description>Secondary outcomes included the comparison of the P2Y12 reaction units (PRU) determined by VerifyNow P2Y12 at 30 min and 2, 4, 8, 24 hours after ticagrelor loading dose administration</description>
          <units>PRU</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231" spread="15"/>
                    <measurement group_id="O2" value="225" spread="17"/>
                    <measurement group_id="O3" value="249" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" spread="28"/>
                    <measurement group_id="O2" value="83" spread="31"/>
                    <measurement group_id="O3" value="148" spread="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" spread="19"/>
                    <measurement group_id="O2" value="46" spread="22"/>
                    <measurement group_id="O3" value="69" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="18"/>
                    <measurement group_id="O2" value="44" spread="21"/>
                    <measurement group_id="O3" value="78" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" spread="13"/>
                    <measurement group_id="O2" value="41" spread="14"/>
                    <measurement group_id="O3" value="72" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity by Vasodilator-stimulated Phosphoprotein (VASP) at All Time Points</title>
        <description>Secondary outcomes included the comparison of the platelet reactivity index (PRI) determined by vasodilator-stimulated phosphoprotein (VASP) at 30 min and 1, 2, 4, 8, 24 hours after ticagrelor loading dose administration</description>
        <time_frame>30 min and 1, 2, 4, 8, 24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 180mg</title>
            <description>Standard ticagrelor 180mg loading dose
Ticagrelor 180mg: Randomization to standard ticagrelor loading dose</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 270mg</title>
            <description>High ticagrelor 270mg loading dose
Ticagrelor 270mg: Randomization to a high ticagrelor loading dose regimen</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 360mg</title>
            <description>High ticagrelor 360mg loading dose
Ticagrelor 360mg: Randomization to a high ticagrelor loading dose regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity by Vasodilator-stimulated Phosphoprotein (VASP) at All Time Points</title>
          <description>Secondary outcomes included the comparison of the platelet reactivity index (PRI) determined by vasodilator-stimulated phosphoprotein (VASP) at 30 min and 1, 2, 4, 8, 24 hours after ticagrelor loading dose administration</description>
          <units>PRI</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" spread="6"/>
                    <measurement group_id="O2" value="81" spread="6"/>
                    <measurement group_id="O3" value="78" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56" spread="7"/>
                    <measurement group_id="O2" value="51" spread="8"/>
                    <measurement group_id="O3" value="78" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" spread="9"/>
                    <measurement group_id="O2" value="39" spread="10"/>
                    <measurement group_id="O3" value="48" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="6"/>
                    <measurement group_id="O2" value="30" spread="7"/>
                    <measurement group_id="O3" value="21" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" spread="5"/>
                    <measurement group_id="O2" value="30" spread="5"/>
                    <measurement group_id="O3" value="23" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" spread="4"/>
                    <measurement group_id="O2" value="30" spread="5"/>
                    <measurement group_id="O3" value="28" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Profiles of Ticagrelor (Tmax)</title>
        <description>Pharmacokinetic assessments included determination of plasma concentration of ticagrelor. Time for the maximum plasma concentration (Tmax), maximum observed plasma concentration (Cmax) and the area under the plasma concentration vs. time curve from time 0 to the last measurable concentration (AUC0-t) were calculated.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 180mg</title>
            <description>Standard ticagrelor 180mg loading dose
Ticagrelor 180mg: Randomization to standard ticagrelor loading dose</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 270mg</title>
            <description>High ticagrelor 270mg loading dose
Ticagrelor 270mg: Randomization to a high ticagrelor loading dose regimen</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 360mg</title>
            <description>High ticagrelor 360mg loading dose
Ticagrelor 360mg: Randomization to a high ticagrelor loading dose regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Profiles of Ticagrelor (Tmax)</title>
          <description>Pharmacokinetic assessments included determination of plasma concentration of ticagrelor. Time for the maximum plasma concentration (Tmax), maximum observed plasma concentration (Cmax) and the area under the plasma concentration vs. time curve from time 0 to the last measurable concentration (AUC0-t) were calculated.</description>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" lower_limit="2" upper_limit="24"/>
                    <measurement group_id="O2" value="5.0" lower_limit="1" upper_limit="24"/>
                    <measurement group_id="O3" value="7.4" lower_limit="2" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Profiles of Ticagrelor (Cmax)</title>
        <description>Pharmacokinetic assessments included determination of plasma concentration of ticagrelor. Time for the maximum plasma concentration (Tmax), maximum observed plasma concentration (Cmax) and the area under the plasma concentration vs. time curve from time 0 to the last measurable concentration (AUC0-t) were calculated.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 180mg</title>
            <description>Standard ticagrelor 180mg loading dose
Ticagrelor 180mg: Randomization to standard ticagrelor loading dose</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 270mg</title>
            <description>High ticagrelor 270mg loading dose
Ticagrelor 270mg: Randomization to a high ticagrelor loading dose regimen</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 360mg</title>
            <description>High ticagrelor 360mg loading dose
Ticagrelor 360mg: Randomization to a high ticagrelor loading dose regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Profiles of Ticagrelor (Cmax)</title>
          <description>Pharmacokinetic assessments included determination of plasma concentration of ticagrelor. Time for the maximum plasma concentration (Tmax), maximum observed plasma concentration (Cmax) and the area under the plasma concentration vs. time curve from time 0 to the last measurable concentration (AUC0-t) were calculated.</description>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="789" lower_limit="95" upper_limit="3550"/>
                    <measurement group_id="O2" value="1208" lower_limit="276" upper_limit="2940"/>
                    <measurement group_id="O3" value="1208" lower_limit="242" upper_limit="4040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Profiles of Ticagrelor (AUC0-t)</title>
        <description>Pharmacokinetic assessments included determination of plasma concentration of ticagrelor. Time for the maximum plasma concentration (Tmax), maximum observed plasma concentration (Cmax) and the area under the plasma concentration vs. time curve from time 0 to the last measurable concentration (AUC0-t) were calculated.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ticagrelor 180mg</title>
            <description>Standard ticagrelor 180mg loading dose
Ticagrelor 180mg: Randomization to standard ticagrelor loading dose</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor 270mg</title>
            <description>High ticagrelor 270mg loading dose
Ticagrelor 270mg: Randomization to a high ticagrelor loading dose regimen</description>
          </group>
          <group group_id="O3">
            <title>Ticagrelor 360mg</title>
            <description>High ticagrelor 360mg loading dose
Ticagrelor 360mg: Randomization to a high ticagrelor loading dose regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Profiles of Ticagrelor (AUC0-t)</title>
          <description>Pharmacokinetic assessments included determination of plasma concentration of ticagrelor. Time for the maximum plasma concentration (Tmax), maximum observed plasma concentration (Cmax) and the area under the plasma concentration vs. time curve from time 0 to the last measurable concentration (AUC0-t) were calculated.</description>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7893" lower_limit="1270" upper_limit="33974"/>
                    <measurement group_id="O2" value="12379" lower_limit="2935" upper_limit="33105"/>
                    <measurement group_id="O3" value="12381" lower_limit="768" upper_limit="66201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>In-hospital adverse events, including ischemic events, bleeding, bradyarrhythmias, and dyspnea, defined according to previously reported criteria in the PLATO trial, were recorded.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ticagrelor 180mg</title>
          <description>Standard ticagrelor 180mg loading dose
Ticagrelor 180mg: Randomization to standard ticagrelor loading dose</description>
        </group>
        <group group_id="E2">
          <title>Ticagrelor 270mg</title>
          <description>High ticagrelor 270mg loading dose
Ticagrelor 270mg: Randomization to a high ticagrelor loading dose regimen</description>
        </group>
        <group group_id="E3">
          <title>Ticagrelor 360mg</title>
          <description>High ticagrelor 360mg loading dose
Ticagrelor 360mg: Randomization to a high ticagrelor loading dose regimen</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic stroke</sub_title>
                <description>One patients in the 270mg group developed a peri-PCI ischemic stroke, which was manged according to standard-of-care.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Major-life threatening bleed</sub_title>
                <description>One patient in the 360mg group experienced a major-life threatening bleed (hypovolemic shock requiring vasopressor and transfusion)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Minimal/minor bleeding</sub_title>
                <description>Vascular access-related bleeding</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was not powered to assess safety or efficacy, which would require larger clinical studies. Although laboratory personnel were blinded to treatment assignment, the study had an open-label design.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dominick J. Angiolillo, MD, PhD</name_or_title>
      <organization>University of Florida - Jacksonville</organization>
      <phone>9042443933</phone>
      <email>dominick.angiolillo@jax.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

